InvestorsHub Logo
Followers 15
Posts 695
Boards Moderated 0
Alias Born 01/09/2013

Re: Ngamblin post# 2625

Saturday, 10/26/2013 11:58:33 AM

Saturday, October 26, 2013 11:58:33 AM

Post# of 4126
Not concerned. Just more saber rattling. Check out link below. Page 8.

CPRX has breakthrough/orphan drug status and presently in phase 3 trials. My understanding was Jacobus was in phase 2, but couldn't find them listed in report.

Are far as investor being hurt, I just don't see it. Anyone who bought before September are even or ahead, and investors who entered after September are underwater due to negative press, not due to any fundamental change in the company. Barring any cataclysmic event, CPRX will receive approval of Firdapse and investors will reap the benefits.

http://phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CPRX News